These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23967714)

  • 1. Pain management in palliative cancer patients: a prospective observational study on the use of high dosages of transdermal buprenorphine.
    Clement PM; Beuselinck B; Mertens PG; Cornelissen P; Menten J
    Acta Clin Belg; 2013; 68(2):87-91. PubMed ID: 23967714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.
    Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O;
    Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
    Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
    J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
    Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal buprenorphine in cancer pain and palliative care.
    Sittl R
    Palliat Med; 2006; 20 Suppl 1():s25-30. PubMed ID: 16764218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
    Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
    Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.
    Sittl R; Griessinger N; Likar R
    Clin Ther; 2003 Jan; 25(1):150-68. PubMed ID: 12637117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
    Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
    J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
    Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
    Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of transdermal buprenorphine to relieve radiotherapy-related pain in head and neck cancer patients.
    Menten J; Carpentier I; Deschutter H; Nuyts S; Van Beek K
    Cancer Invest; 2013 Jul; 31(6):412-20. PubMed ID: 23758187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group].
    Greco MT; Deandrea S; Corli O; Montanari M; Caraceni A; Apolone G;
    Recenti Prog Med; 2008 Nov; 99(11):538-51. PubMed ID: 19209537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.